Skip to main content
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc — Investor Relations & Filings

Ticker · MGTX ISIN · KYG596651029 LEI · 54930007YV6NYIOGFZ57 US Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2024-05-09 Earnings Release
Country KY Cayman Islands
Listing US MGTX

About MeiraGTx Holdings plc

https://meiragtx.com/

MeiraGTx Holdings plc is a clinical-stage genetic medicine company developing therapies for both rare and prevalent diseases. The company's primary focus areas include disorders of the eye, salivary gland, and central nervous system. MeiraGTx utilizes a proprietary riboswitch gene regulation platform designed to provide precise spatial and temporal control of gene expression. As a vertically integrated entity, it possesses end-to-end capabilities, including its own cGMP manufacturing facilities, to support a broad pipeline of therapeutic candidates. The company has multiple programs in clinical development, with several in late-stage trials.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2024. The text states that the press release is furnished as an exhibit and incorporated by reference, but the document itself does not contain the full financial results or detailed financial statements. The document length is 3866 characters, which is relatively short and consistent with a current report filing announcing an earnings release rather than the earnings release itself. According to the rules, such a filing that announces or furnishes a press release of quarterly financial results is classified as an Earnings Release (ER).
2024-05-09 English
ARS
Annual Report
2024-04-25 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes voting items such as election of directors, advisory votes on executive compensation, and ratification of the independent auditor. The document is titled 'Definitive Additional Materials' and is related to the Annual Meeting of MeiraGTx Holdings plc. It is not the proxy statement itself but additional materials for the meeting. The content focuses on proxy solicitation and voting information rather than the actual meeting minutes or financial reports. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains substantive proxy solicitation content, not just an announcement of a report, so it is not an RPA or RNS. Hence, the best classification is PSI with high confidence.
2024-04-25 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-25 English
8-K/A
Board/Management Information Classification · 100% confidence The document is a Form 8-K/A filed with the SEC, specifically an amendment to a previous Form 8-K. The content focuses on the appointment of Dr. Debra Yu to the company's Board of Directors and her committee assignments. This relates to changes in the company's board or senior management. There are no financial statements or detailed financial data present, so it is not an annual or quarterly report. The document is clearly about board/management information, fitting the category of announcements about changes in the company's board or senior management.
2024-04-16 English
Director's Dealing 2024
Director's Dealing
2024-04-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.